TY - JOUR T1 - Differentially expressed circular RNAs in peripheral blood mononuclear cells of PD patients JF - medRxiv DO - 10.1101/2020.11.14.20231779 SP - 2020.11.14.20231779 AU - Stylianos Ravanidis AU - Anastasia Bougea AU - Dimitra Karampatsi AU - Nikolaos Papagiannakis AU - Matina Maniati AU - Leonidas Stefanis AU - Epaminondas Doxakis Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/16/2020.11.14.20231779.abstract N2 - Background New noninvasive and affordable molecular approaches that will complement current practices and increase the accuracy of PD diagnosis are urgently needed. CircRNAs are highly stable non-coding RNAs that accumulate with aging in neurons and are increasingly shown to regulate all aspects of neuronal development and function.Objectives The aims of the present study were to identify differentially expressed circRNAs in PBMCs of idiopathic PD patients and explore the competing endogenous RNA networks affected.Methods Eighty-seven circRNAs were initially selected based on relatively high gene expression in the human brain. Over half of these were readily detectable in PBMCs using RT-qPCR. Comparative expression analysis was then performed in PBMCs from sixty controls and sixty idiopathic subjects with PD.Results Six circRNAs derived from MAPK9, HOMER1, SLAIN1, DOP1B, REPS1, and PSEN1 transcripts were significantly downregulated in PD patients. The classifier that best distinguished PD consisted of four circRNAs with an AUC of 0.84. CLIP-Seq data revealed that the RNA binding proteins bound by most of the deregulated circRNAs include the neurodegeneration-associated FUS, TDP43, FMR1 and ATXN2. MicroRNAs predicted to be sequestered by most deregulated circRNAs had the GOslim categories ‘Protein modification’, ‘Transcription factor activity’ and ‘Cytoskeletal protein binding’ mostly enriched.Conclusions This is the first study that identifies circRNAs deregulated in the peripheral blood of PD patients. They may serve as diagnostic biomarkers and since they are highly expressed in the brain and are derived from genes with essential brain functions, they may also hint on the PD pathways affected.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was financed by Greece and European Union (European Social Fund‐ESF) through the Operational Program, Human Resources, Development, Education and Lifelong Learning 2014‐2020 in the context of the project Development of diagnostic biomarker tests for Parkinson's disease (MIS 5049385). It was also co-financed by the action Precision medicine Hellenic network in genetic neurodegenerative diseases (2018ΣΕ01300001) of the Hellenic public investments program of GSRT and the Michael J. Fox Foundation for Parkinson's Research (Grant ID 13353). The authors have received no payments or services from a third party for any aspect of the submitted work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Eginition hospital and BRFAA ethics committees approved the study and all participants provided written consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets analysed during the current study are all available from the corresponding author on request.6-OHDA6-hydroxydopamineANCOVAanalysis of covarianceANOVAanalysis of varianceAPPamyloid-beta precursor proteinAUCarea under the curvecircRNAcircular RNACTcomputed tomographyDOP1BDOP1 leucine zipper like proteinFTDFrontotemporal dementiaGOgene ontologyH&YHoehn & YahrHChealthy controlHDAChistone deacetylaseHOMER1homer scaffold protein 1hsahomo sapiensiPDidiopathic PDKEGGKyoto encyclopedia of genes and genomesLEDDLevodopa equivalent daily doseLPSlipopolysaccharidesMAPK9mitogen-activated protein kinase 9MMSEMini Mental State ExaminationMRImagnetic resonance imagingNBIAneurodegeneration with brain iron accumulationPDParkinson’s diseasePSEN1presenilin 1REPS1RALBP1 associated eps domain containing 1SNCAalpha-synucleinSLAIN1SLAIN motif family memberUPDRSunified Parkinson’s disease rating scaleTARDBPTAR DNA Binding ProteinUTRuntranslated region ER -